
TransMedics Group TMDX
$ 85.17
-9.47%
TransMedics Group General and Administrative Expenses | TMDX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses TransMedics Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 185 M | 169 M | 120 M | 69.9 M | 38.3 M | 24.2 M | 23.6 M | 12.3 M | 7.61 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 185 M | 7.61 M | 72.1 M |
Quarterly General and Administrative Expenses TransMedics Group
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.3 M | 57.8 M | 63 M | 51.4 M | 46 M | 44.1 M | 43.6 M | 46.9 M | 42.7 M | 42.9 M | 36.2 M | 34.6 M | 30.7 M | 29.4 M | 25 M | 21.7 M | 16.9 M | 17.4 M | 13.9 M | 12 M | 10.3 M | 9.16 M | 6.79 M | 6.18 M | 5.49 M | 5.87 M | 6.65 M | 6.17 M | 6.52 M | 6.25 M | 4.65 M | - | 2.8 M | 2.9 M | 2.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 63 M | 2.24 M | 24.1 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
EDAP TMS S.A.
EDAP
|
14.1 M | - | - | $ 162 M | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
Zynex
ZYXI
|
60.4 M | - | - | $ 21.1 M | ||
|
Invacare Corporation
IVC
|
227 M | - | - | $ 24.7 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
CONMED Corporation
CNMD
|
132 M | $ 46.69 | 0.39 % | $ 1.45 B | ||
|
ShockWave Medical
SWAV
|
95.3 M | - | - | $ 12.3 B | ||
|
Nevro Corp.
NVRO
|
310 M | - | - | $ 217 M | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
Axonics Modulation Technologies
AXNX
|
45.8 M | - | - | $ 3.31 B | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
ThermoGenesis Holdings
THMO
|
7.22 M | - | -25.84 % | $ 171 K | ||
|
Talis Biomedical Corporation
TLIS
|
28.2 M | - | 3.55 % | $ 7.96 M | ||
|
Abiomed
ABMD
|
423 M | - | - | $ 17.2 B | ||
|
Titan Medical
TMDI
|
12.4 M | - | -26.32 % | $ 19.6 M | ||
|
SmileDirectClub
SDC
|
279 M | - | -53.45 % | $ 9.71 M | ||
|
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | ||
|
Sientra
SIEN
|
41.5 M | - | -16.59 % | $ 10.3 M | ||
|
Acutus Medical
AFIB
|
10.4 M | - | -26.83 % | $ 2.62 M | ||
|
Viveve Medical
VIVE
|
12.5 M | - | -15.35 % | $ 1.71 M | ||
|
MiMedx Group
MDXG
|
56.5 M | $ 3.06 | -1.77 % | $ 452 M | ||
|
Venus Concept
VERO
|
36.5 M | - | - | $ 726 K | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
Surgalign Holdings
SRGA
|
95.9 M | - | -32.98 % | $ 1.68 M | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
SeaSpine Holdings Corporation
SPNE
|
42.9 M | - | 0.28 % | $ 270 M | ||
|
Inari Medical
NARI
|
361 M | - | - | $ 4.23 B | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
NuVasive
NUVA
|
634 M | - | - | $ 2.07 B | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
ViewRay
VRAY
|
52.4 M | - | 1.54 % | $ 468 M | ||
|
Medigus Ltd.
MDGS
|
7.22 M | - | 10.28 % | $ 55.5 M | ||
|
Abbott Laboratories
ABT
|
12.3 B | $ 103.08 | -0.98 % | $ 179 B | ||
|
Align Technology
ALGN
|
1.76 B | $ 154.77 | -3.07 % | $ 11.2 B | ||
|
Vapotherm
VAPO
|
19.3 M | - | 6.72 % | $ 34 M | ||
|
Silk Road Medical, Inc
SILK
|
145 M | - | - | $ 1.07 B | ||
|
Alphatec Holdings
ATEC
|
499 M | $ 6.66 | -3.48 % | $ 999 M | ||
|
Boston Scientific Corporation
BSX
|
6.89 B | $ 41.95 | -2.43 % | $ 62.1 B | ||
|
Natus Medical Incorporated
NTUS
|
52.8 M | - | 1.94 % | $ 1.05 B | ||
|
Nemaura Medical
NMRD
|
5.6 M | - | -17.8 % | $ 2.74 M | ||
|
Butterfly Network
BFLY
|
39.2 M | $ 5.39 | -8.28 % | $ 1.33 B | ||
|
Bio-Rad Laboratories
BIO
|
844 M | $ 358.56 | -2.43 % | $ 9.78 B | ||
|
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 101.86 | -1.94 % | $ 59.6 B | ||
|
Aethlon Medical
AEMD
|
2.7 M | $ 5.49 | 13.33 % | $ 3.7 M | ||
|
Apyx Medical Corporation
APYX
|
15.8 M | $ 2.39 | 2.06 % | $ 98.2 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Cognyte Software Ltd.
CGNT
|
47.1 M | $ 7.27 | -6.56 % | $ 530 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
Medtronic PLC
MDT
|
11.8 B | $ 99.64 | -1.0 % | $ 128 B |